Jobs
View more job listings or post a job
Bioduro-Sundia Associate Director/Director in Laboratory Animal and Exploratory Toxicology
Variant Bio (Senior) Scientist - DMPK
Alturas Analytics Scientist 1
University of California, Davis TOXICOLOGY ANALYTICAL CHEMIST (STAFF RESEARCH ASSOCIATE 3)
University of California, Davis CALIFORNIA ANIMAL HEALTH AND FOOD SAFETY LABORATORY - TOXICOLOGY LAB RESEARCH SUPERVISOR/GROUP LEADER
Eli Lilly and Company R-39973 Scientific Director ADME - Novel Modalities (Open)
FibroGen Director DMPK
Applied BioMath Technical Marketing Specialist
Horizon Therapeutics Director, Bioanalytical Sciences
Exelixis Principal Scientist - DMPK
Post a job

Workshop

Antibody Drug Discovery and Development: Hit Generation, Engineering, Cell-line Development, IND enabling studies, and Biosimilars


Speakers: Donald McCarthy, Mohan Srinivasan, Guna Kannan, Erin Filbert, Deepali Sawant, Bo Yu, Nicola Stagg, Richard Boismenu
Organizers: Donald McCarthy, Mohan Srinivasan, Wenfeng Xu
Date: 2019-11-12
Time: 8:45-17:00 Pacific Time
Registration fee: (USD): Regular: $195; Academic: $125; For unemployed or students: $30; For vendor-show rep: $35; For major-sponsor rep (incl lunch): $0
Location: SF Bay Area: Foster City Crowne Plaza
Major Sponsor: (2)Abzena; Sygnature Discovery;(Major Sponsorship - lunch session still open)
Vendor show vendors registered to date: (13)BioIVT; ChemPartner; Emerson Collective; Eurofins Discovery; Genscript USA; Intertek; JOINN Biologics; MabPlex USA, Inc.; MicroConstants; PHC former Panasonic Healthcare; Promega; R&D Systems; SCIEX
Registration: http://www.PBSS.org
Registration deadline:2019-11-10  (it will close sooner if the seating cap is reached)

About the Topic

Workshop Agenda:

8:45 - 9:00. PBSS Welcome Remarks - Shichang Miao 

9:00 - 9:30. 1. Overview of Therapeutic mAbs - Donald McCarthy, Panorama Reserach Institute 

9:30 - 10:30. 2. Antibody Discovery - Mohan Srinivasan, TRex Bio

10:30 - 10:40. Major Sponsor Presentation - Abzena

10:40 - 11:00. Break

11:00 - 12:00. 3. Antibody Engineering - Guna Kannan, Denali

12:00 - 12:30. 4. In-vitro Assays for Antibody Discovery & Development - Erin Filbert, Apexigen

12:30 - 1:30. Lunch

1:30 - 2:00. 5. In-vivo Models for Antibody Discovery & Clinical Efficacy - Deepali Sawant, Amgen

2:00 - 2:50. 6. Cell Line Development & CMC - Bo Yu

2:50 – 3:00. Major Sponsor Presentation - Cytovance Biologics

3:00 - 3:20. Break & Raffle

3:20 - 4:15. 7. IND Enabling Studies - Nicola Stagg, Genentech

4:15 – 5:00. 8. Biosimilars - Richard Boismenu, Coherus

5:00 – 5:30. 9. Panel Discussion - All Speakers

 

Organizing Committee: Donald McCarthy, Mohan Srinivasan, Wenfeng Xu

 


2024-04-26, [In-Person] Oncology Clinical Dose Optimization in Light of FDA Project Optimus
2024-05-06, [In-Person] Human Mass Balance and Metabolite Profiling Studies: Strategies, Technical Approaches, Regulatory Guidance, Applications and Case Studies
2024-05-13, [Free Online] Highlights of 2023 FDA Drug Approvals
2024-05-21, [In-Person] Nonclinical Safety Studies for IND and NDA Filing for Small Molecules: Nuts, Bolts and Best Practices
2024-05-30, [Free Online Workshop] Career Transition for Research Scientists: Career Overview, Project Management and Regulatory Affairs (jointly with BioPharmaPM and RAPS-SF)
2024-06-13, [In-Person] CMC Strategies and Activities for IND and NDA Filing for Small Molecules: Nuts, Bolts and Best Practices
2024-06-20, Alzheimer's Disease: untangling what we thought we knew and future Precision Medicine Diagnostics and Therapeutics
2024-07-24, [Free Online] The Science and Stories of Promising Biotech Startups: Symposium No.6
2024-09-10, [In-Person] Rethinking Translational PK/PD and Human Dose Projections for Novel Therapeutic Modalities: Covalent Inhibitors, PROTACs, Molecular Glues, ADCs, Ocular and Neuro delivery, Vaccines, Bispecifics, Cell and Gene Therapies
2024-09-20, [In-Person] Non-clinical safety assessments of biologics and novel modalities for IND/NDA Filing: Nuts, Bolts and Best Practices
2024-10-10, [In-Person] Regulatory Global Submission: Strategies and Best Practices for FDA, EMA and PMDA
©Pharmaceutical & BioScience Society, International; Last Modified: 4/19/2024; Admin Logon
Ads (in random order)
Submit a Text Ad
($250 for 2 months)

Lena Biosciences Predictive toxicology. Intrinsic & idiosyncratic drug-induced liver injury. Mitochondrial toxicity in a drug metabolism-competent model.
Hypha Discovery Synthesis, purification & NMR characterization of phase I and II drug metabolites & API impurities at mg-g scale with COAs.
Lena Biosciences Predictive toxicology. Mitochondrial toxicity in a drug metabolism-competent model with active transporters. Intrinsic & idiosyncratic DILI.
Alturas Analytics, Inc. Expert Regulated & Non-Regulated LC-MS, GC-MS bioanalytical & PK/TK analysis of small & large molecules in any matrix. Discovery through phase IV.
Submit a Text Ad